Skip to main content
Premium Trial:

Request an Annual Quote

Nanosphere Q3 Revenues Spike Sharply

NEW YORK (GenomeWeb News) – Nanosphere today said that revenues for its third quarter rose nearly three-fold on sales of its Verigene Gram-Positive Blood Culture Test.

For the three months ended Sept. 30, the Northbrook, Ill.-based molecular diagnostics company said that revenues increased to $2.4 million from $865,000 a year ago, missing the average Wall Street expectation of $2.6 million.

The company said that the year-over-year increase was driven by the blood culture test, which was cleared by the US Food and Drug Administration in June 2012. Nanosphere achieved 45 new customer placements during the third quarter and reaffirmed its full-year 2013 new customer placement guidance of between 150 and 200.

The firm's net loss in the quarter was $9.4 million, or $.16 per share, compared to a net loss of $8.7 million, or $.16 per share, a year ago. Analysts had estimated, on average, a net loss per share of $.15.

Its R&D spending dropped to $3.9 million, down 15 percent from $4.6 million during the second quarter of 2012. SG&A costs rose 39 percent to $6.1 million from $4.4 million as Nanosphere expanded its sales and customer support teams, while clinical trial expenses in support of the company's pipeline rose.

Nanosphere ended the quarter with $49.3 million in cash and cash equivalents. The firm netted $27.7 million from a public offering in September.

"We continue to make progress in delivering value to our customers through our menu of infectious disease tests," Nanosphere President and CEO Michael McGarrity said in a statement. "The proceeds from our underwritten registered direct offering afford us the balance sheet strength to execute on our operating plan and make the necessary investment to continue building a sustainable world-class molecular diagnostics company."

The company reaffirmed its full-year 2013 revenue guidance of between $10 million and $11 million, which had been lowered in the second quarter from an earlier guidance of between $13 million and $15 million.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.